Authorisation on the acquisition of the Company's own
shares
The Annual General
Meeting 3 April 2025 authorised the Board of Directors to decide on the
acquisition of the Company's own shares in one or more tranches. The maximum
number of own shares that may be purchased is 700,000 shares, and own shares
may be purchased using the unrestricted shareholders' equity. The own shares can be acquired at a price formed in public trading on the acquisition date or at a price otherwise formed on the market. In the acquisition, derivatives, inter alia, can be used. The acquisition of own shares may be made otherwise than in proportion to the share ownership of the shareholders (directed acquisition). Own shares acquired by the Company may be held by it, cancelled or transferred. The authorisation includes the right of the Board of Directors to resolve on how the own shares are acquired as well as to decide on other matters related to the acquisition of own shares. The authorisation is valid until the following Annual
General Meeting, however not longer than until 30 June 2026.
Authorisation on the issuance of shares and the transfer
of special rights entitling to shares
The Annual
General Meeting 3 April 2025 authorised the Board of Directors to decide on the
issuance of shares and on the transfer of special rights entitling to shares
referred to in chapter 10, section 1 of the Limited Liability Companies Act, in
one or more tranches, either against or without consideration. The number of
shares to be issued, including shares transferred under special rights, may not
exceed 800,000 shares. The Board of Directors may decide to issue either new
shares or to transfer any treasury shares held by the Company.
The Board of
Directors is entitled to decide on all terms of the share issue and transfer of
special rights entitling to shares, including the right to deviate from the
shareholders' pre-emptive right.
The
authorisation shall be valid until the following Annual General
Meeting, however not longer than until 30 June 2026.